IP Verse

Compositions And Methods For Tcr Reprogramming Using Fusion Proteins

Patent No. EP3298033 (titled "Compositions And Methods For Tcr Reprogramming Using Fusion Proteins") was filed by TCR Therapeutics on May 18, 2016. The application was issued on Jul 12, 2023.

Patent Summary

Fusion proteins for cancer immunotherapy that combine a T-cell receptor (TCR) extracellular domain with an antibody binding domain to target cancer cells. The fusion proteins (TCR fusion proteins or TFPs) are expressed in T-cells to create chimeric receptors that can specifically recognize and kill cancer cells. They have the potential to overcome limitations of CAR-T cell therapy by broadly targeting different tumor types and releasing lower levels of cytokines. The TFPs can be incorporated into TCR complexes and functionally interact with endogenous TCR components. The TCR extracellular domain provides specificity for tumor antigens and the antibody domain provides tumor binding.

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
JONES DAYMay 4, 2021JONES DAY

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3298033

TCR THERAPEUTICS
Application Number
EP16797244A
Filing Date
May 18, 2016
Status
Patent Maintained As Amended
Jun 9, 2023
Publication Date
Jul 12, 2023
External Links
Slate, Register , Google Patents